Clinical trials: Immunity to COVID-19
Corona Virus Infection, Flu Vaccine
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19…
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Trial name
- NCT04579588
- Testing
- Flu shot
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Stanford University
Immune Response to Covid 19 Vaccination
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied .
- Trial name
- NCT05408299
- Testing
- Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- National Research Centre, Egypt
Covid19, SARS-CoV Infection
COVID-19 in Polish Ice Swimmers.
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections.
- Conditions
- Covid19, SARS-CoV Infection, Resistance, Disease, Hypothermia
- Trial name
- ICE (NCT04817280)
- Testing
- Ice Swimming
- Where
- 3 sites in Poland
- Volunteers
- 2,534 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
COVID-19
Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica
Describe the immune response of patients affected by SARS-CoV-2, including an assessment of the types of antibodies elicited by the infection, specifc antibody titers for the different isotypes, evolution of the antibody response…
- Trial name
- RESPIRA (NCT04537338)
- Testing
- 1. Characterize the immune response after infection with SARS-CoV-2
- Volunteers
- 2,000 people
- Sponsor
- Agencia Costarricense de Investigaciones Biomedicas
COVID-19
Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand
The investigators assessed the effect of treatment for COVID and immunity of the volunteers who admitted to the home isolation.
- Trial name
- NCT05328479
- Where
- Thailand
- Volunteers
- 5,181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
SARS-CoV2 Infection Common Pathogens, Diabetes Mellitus, Type 1
Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- TIRID (NCT05171998)
- Testing
- venous blood sample
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Cancer, Hematopoietic System--Cancer
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.
- Conditions
- Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy
- Trial name
- NCT05164016
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Coronavirus
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19.
- Trial name
- NCT04373148
- Testing
- There is no intervention
- Where
- 2 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS-CoV 2, COVID-19
COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists.
- Trial name
- CiaoCorona (NCT04448717)
- Testing
- COVID-19 Antibody testing
- Where
- Switzerland
- Volunteers
- 4,250 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Cancer
A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study
This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer patients (age and gender…
- Trial name
- NCT04800146
- Testing
- Blood sample
- Where
- Switzerland
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Ilaria Colombo
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
COVID-19
Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain
The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vaccine pivotal studies supported…
- Trial name
- NCT05398718
- Testing
- Sotrovimab
- Where
- Bahrain
- Volunteers
- 20,000 people
- Sponsor
- Abu Dhabi Health Services Company
COVID - 19
Retail COVID-19 Study
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection.
- Trial name
- NCT06761612
- Testing
- FDA approved mRNA vaccines
- Where
- 20 sites in United States
- Volunteers
- 2,519 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
COVID-19, SARS-CoV-2
Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2
To evaluate host-immune biomarkers including TRAIL, IP-10, CRP and their computational integration for predicting COVID-19 and disease severity in patients with PCR-confirmed COVID-19.
- Conditions
- COVID-19, SARS-CoV-2, Viral Infection
- Trial name
- DIRECTOR (NCT04655521)
- Where
- Germany
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Respiratory Tract Infections (RTI), Mucosal Immunity
To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children
The goal of this observational study is to answer a few questions about respiratory tract infections in South African children: 1.
- Trial name
- Muco-Kids (NCT06902194)
- Where
- 2 sites in South Africa
- Volunteers
- 250 people
- Sponsor
- Desmond Tutu TB Centre
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax